Trials / Unknown
UnknownNCT03692689
Safety and Efficacy of SCT200 in Patients With Relapsed or Metastatic Triple Receptor Negative Breast Cancer
Recombinant Anti-EGFR Monoclonal Antibody（SCT200） in Patients With Relapsed or Metastatic Triple Receptor Negative Breast Cancer : a Phase Ⅱ, Open-label, Single-arm, Multicenter Study
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Sinocelltech Ltd. · Industry
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of recombinant anti-EGFR monoclonal antibody（SCT200）in patients with triple receptor negative breast cancer treated after failure of standard therapy (including Anthracyclines and/or Taxanes).
Detailed description
This open label,single-arm multicenter phase II study is designed to evaluate Objective Response Rate (ORR) in advanced triple receptor negative breast cancer treated with anti-EGFR monoclonal antibody SCT200.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | SCT200 | Recombinant Anti-EGFR Monoclonal Antibody（SCT200） |
Timeline
- Start date
- 2018-07-20
- Primary completion
- 2019-09-30
- Completion
- 2019-12-31
- First posted
- 2018-10-02
- Last updated
- 2018-10-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03692689. Inclusion in this directory is not an endorsement.